Skip to main content
main-content

Bimekizumab: Dual IL-17A/IL-17F inhibition in spondyloarthritis

What you need to know

Bimekizumab – a monoclonal antibody that inhibits both interleukin (IL)-17A and IL-17F – has shown promise in phase 3 trials across the spectrum of spondyloarthritis. Take a look at this page for a quick-reference summary of the data in psoriatic arthritis and axial spondyloarthritis, expert opinion on what the trial results might mean for clinical practice, and the latest news on research and regulatory approvals.

At a glance

A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

Summary of the phase 3 trials investigating the IL-17A/IL-17F inhibitor bimekizumab in patients with ankylosing spondylitis, nonradiographic axial spondyloarthritis, or psoriatic arthritis.

Phase 3 trials of bimekizumab in PsA

Close up of subcutaneous injection into stomach

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.

Joseph Merola

07-06-2022 | EULAR 2022 | Conference coverage | Video

The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.

Philippe Carron

15-06-2022 | EULAR 2022 | Conference coverage | Video

BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice?

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.

Phase 3 trials of bimekizumab in axSpA

X-ray lumbo-sacral spine and pelvis and

01-06-2022 | EULAR 2022 | Conference coverage | News

BE MOBILE trials support bimekizumab for the treatment of axSpA

The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.

Désirée van der Heijde

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis.

Fabian Proft

20-06-2022 | EULAR 2022 | Conference coverage | Video

BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials.

Related news

19-07-2022 | Bimekizumab | News

Bimekizumab demonstrates sustained benefits in PsA, ankylosing spondylitis

Follow-up results from the BE ACTIVE and BE AGILE phase 2b trials show that the efficacy and safety profiles of bimekizumab are maintained for up to 3 years in patients with psoriatic arthritis or ankylosing spondylitis.

12-11-2019 | Ankylosing spondylitis | ACR/ARP 2019 | News

Bimekizumab benefits for ankylosing spondylitis extend beyond 12 weeks

Bimekizumab shows sustained benefit in the treatment of patients with ankylosing spondylitis, 48-week data show.

14-06-2019 | Axial spondyloarthritis | EULAR 2019 | News

BE AGILE: Bimekizumab shows promise for ankylosing spondylitis

Bimekizumab may offer a new therapeutic option for patients with ankylosing spondylitis, findings from the BE AGILE study indicate.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox